A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF
Justin D Lutz, Neha Maharao, Tyrell Simkins, Kathleen Cheplo, Genzhou Liu, Camelia Dumitrescu, Adrienne Griffith, Rajaa Sukhun, Stephen B Heitner, Stuart Kupfer, Polina German · 2026
Read A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF by Justin D Lutz, Neha Maharao, Tyrell Simkins, Kathleen Cheplo, Genzhou Liu, Camelia Dumitrescu, Adrienne Griffith, Rajaa Sukhun, Stephen B Heitner, Stuart Kupfer, Polina German (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624000.txt.
Description
Justin D Lutz and co-authors report the first human study of a new heart drug, ulacamten. Their 2026 study tests a molecule that dampens cardiac myosin, the motor protein of heart muscle. It is aimed at heart failure where the heart still squeezes well but relaxes poorly.
Healthy adults took single or repeated doses in a blinded, placebo-controlled design, with a food-effect arm as well. Doses ranged widely across groups, and heart imaging tracked drug action for a day after each dose. The drug was absorbed steadily, lasted most of a day in the blood, and rose in line with dose. Safety and tolerance were the main outcomes at this stage. First-in-human data of this kind decide whether a drug earns patient trials.
Catalog record
| CREATOR | Justin D Lutz, Neha Maharao, Tyrell Simkins, Kathleen Cheplo, Genzhou Liu, Camelia Dumitrescu, Adrienne Griffith, Rajaa Sukhun, Stephen B Heitner, Stuart Kupfer, Polina German |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |